Clinical Trials for Small Cell Lung Cancer

A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10).

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with previously untreated, locally advanced or metastatic non-squamous NSCLC, high PD-L1 expression (TC ≥ 50%), and no EGFR/ALK/ROS1 alterations, randomizing to either datopotamab deruxtecan (a TROP2-directed ADC) plus rilvegostomig (a bispecific PD-1/TIGIT antibody), rilvegostomig alone, or pembrolizumab monotherapy as first-line therapy. Eligible patients must have ECOG 0-1 and no prior systemic therapy for advanced disease.

ClinicalTrials.gov ID: NCT06357533

A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic NSCLC harboring uncommon EGFR mutations (excluding those with active CNS metastases or prior EGFR TKI use) to receive sutetinib, an investigational irreversible EGFR tyrosine kinase inhibitor, given orally in 28-day cycles.

ClinicalTrials.gov ID: NCT06010329

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic NSCLC (stage IIIB/C or IV), PD-L1 ≥50%, who are current or former smokers and lack actionable driver mutations, comparing cemiplimab (anti-PD-1) monotherapy to its combination with fianlimab, an investigational anti-LAG-3 antibody. Never-smokers and those with EGFR, ALK, or ROS1 alterations are excluded.

ClinicalTrials.gov ID: NCT05785767

A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with advanced, EGFR-mutated, non-squamous NSCLC who have progressed after prior EGFR TKI therapy, randomizing them to either sacituzumab tirumotecan (a TROP2-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor) or standard platinum-based chemotherapy with pemetrexed and carboplatin.

ClinicalTrials.gov ID: NCT06305754

A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Eligible patients are adults with advanced (stage IIIB/C or IV) non-small cell lung cancer lacking EGFR/ALK alterations, randomized to receive either BNT327—a bispecific antibody targeting PD-L1 and VEGF-A—in combination with chemotherapy, or standard pembrolizumab plus chemotherapy as first-line treatment.

ClinicalTrials.gov ID: NCT06712316

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion or other uncommon EGFR mutations (excluding C797S), including those previously treated with ex20ins agents, untreated, or with active brain metastases, to receive zipalertinib, an oral, irreversible EGFR tyrosine kinase inhibitor selective for mutant EGFR. All patients receive zipalertinib monotherapy until progression or withdrawal.

ClinicalTrials.gov ID: NCT05967689

A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic nonsquamous NSCLC with EGFR mutations or other actionable genomic alterations who have progressed after EGFR TKI and platinum chemotherapy, randomizing them to sacituzumab tirumotecan (an anti-TROP2 antibody-drug conjugate with a topoisomerase I inhibitor payload) versus standard chemotherapy (docetaxel or pemetrexed). Eligible patients must have good performance status (ECOG 0-1).

ClinicalTrials.gov ID: NCT06074588

Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with previously untreated, metastatic squamous non-small cell lung cancer (ECOG 0-1) who receive induction with pembrolizumab plus carboplatin and paclitaxel or nab-paclitaxel, then are randomized at maintenance to pembrolizumab alone or in combination with sacituzumab tirumotecan, a TROP2-directed antibody-drug conjugate linked to a topoisomerase I inhibitor.

ClinicalTrials.gov ID: NCT06422143

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with untreated, stage IV squamous NSCLC whose tumors have PD-L1 expression ≥1%, randomizing them to receive first-line platinum-based chemotherapy combined with either rilvegostomig—a bispecific antibody targeting PD-1 and TIGIT—or pembrolizumab, each followed by their respective monotherapy as maintenance. Key exclusions are prior immunotherapy, active CNS disease, and significant autoimmune or infectious disorders.

ClinicalTrials.gov ID: NCT06692738

A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls HLA-A2 positive patients with metastatic squamous or non-squamous NSCLC who have developed secondary resistance to immune checkpoint inhibitors and are ineligible for targeted therapies, randomizing them to receive either OSE2101, a neoepitope-based cancer vaccine designed to stimulate tumor-specific cytotoxic T-cell responses, or standard docetaxel chemotherapy.

ClinicalTrials.gov ID: NCT06472245